InspireMD

Explore the layers of carotid stent innovation

CGuard® features a dual-layer design with a finely woven, non-metallic MicroNet™ mesh outer layer and an inner stent frame enhanced with SmartFit™ technology.1

MicroNet Mesh-Covered Protection

  • Made from polyethylene terephthalate (PET), a non-metallic material, to enhance endothelialization and lower the risk of thrombosis
  • Closed-cell protection against plaque protrusion with the smallest mesh pore size (~150 – 180 μm)*
  • Defense demonstrated beyond 5 years1**
More Mesh

SmartFit Technology

  • Self-expanding nitinol stent
  • The largest open-cell frame* that allows for flexibility even in challenging or complex anatomies
  • Supports accurate vessel wall apposition without the need for tapered configurations
More Flex
cguard-prime-hero

A strong defense against the risk of both early and late embolization

cguard-prime-tablet
The lowest independently adjudicated 30-day and 1-year primary endpoint major adverse event rates of any pivotal study of carotid intervention2-11
Review More Clinical Evidence

MicroNet™ Mesh-Cover

A finely woven layer of defense
Patented MicroNet mesh technology is designed to reduce stroke during and after cartoid artery stenting
cguard-prime-next-level
Next-level embolization prevention
Traps and seals thrombus and plaque against the vessel wall
cguard-prime-layer-2
Full-length embolic protection
Secured at both the distal and proximal crowns for consistent containment
cguard-prime-layer-3
Non-metallic matters
  • Woven from a single 20μm strand of polyethylene terephthalate (PET)
  • Chosen for biostability and non-thrombogenicity
  • Provides optimal pore size to prevent embolization (average 165μm)

Provides lasting protection against restenosis, reducing the need for reintervention2

cguard-prime-surgeon-promotes-healing
bg-cguard-prime-design

Designed to defend in a broad range of anatomies

SmartFit™ Technology simplifies sizing and eliminates the need for tapered configurations while maintaining optimal placement length regardless of vessel diameter12,13

Flexible

Nitinol frame design on a large open-stent cell platform

Accurate

Minimal foreshortening during placement and predictable coverage upon deployment

Conformable

Encourages natural vessel wall apposition after deployment, mitigating restenosis and reducing thrombus formation

edu-cgp-001-01-conformable
Highly conformable
edu-cgp-001-01-apposition
Designed for complete apposition
SmartFit™ enhances conformability and apposition regardless of vessel tortuosity or diameter
edu-cg-035-01-apposition-macro
edu-cg-035-01-apposition-microct
Tortuous apposition
edu-cg-035-01-conformability-macro
edu-cg-035-01-conformability-microct
Conformability at inner diameter step from 7 to 5 mm
Instructions For Use Summary of Safety and Effectiveness Data

CAUTION: Federal (USA) law restricts these devices to sale by or on the order of a physician. See instructions for use for full prescribing information.

The CGuard Prime Carotid Stent System, when used in conjunction with embolic protection devices specified in the labeling, is indicated for improving carotid luminal diameter in patients at high risk for adverse events from carotid endarterectomy who require carotid revascularization and meet both criteria outlined below:

  • Patients with neurological symptoms and ≥ 50% stenosis of the common or internal carotid artery by angiogram, or patients without neurological symptoms and ≥ 80% stenosis of the common or internal carotid artery by angiogram.
  • Patients having a vessel with reference diameters between 6.4mm and 9.0mm at the target lesion.

The CGuard Prime Carotid Stent System should be used in conjunction with the Abbott Emboshield NAV6™ Embolic Protection System or the Medtronic Mo.Ma™ Ultra Proximal Cerebral Protection Device.

CGuard® and the InspireMD Logo are registered trademarks of InspireMD, Inc.

Abbott® and Emboshield NAV6™ are registered trademarks of Abbott Laboratories.

Medtronic® and Mo.Ma™ are registered trademarks of Medtronic Corporation.

References:

  1. Musialek P et al. PARADIGM-Extend Prospective Academic Trial: Accumulating long-term evidence for MicroNet™-covered stent safety and stroke prevention efficacy. Presentation at ESC Congress 2019, Paris, France, 31 August 2019 to 4 September 2019.
  2. InspireMD, Inc. C-GUARDIANS Pivotal Trial: Primary Endpoint Clinical Study Report. Version F (Protocol PRO-9017).
  3. Yadav JS, et al. N Engl J Med. 2004 Oct;351(15):1493-1501. doi: 10.1056/ NEJMoa040127.
  4. Matsumura JS, et al. J Vasc Surg. 2012 Apr;55(4):968-76. doi: 10.1016/j.jvs.2011.10.120.
  5. Higashida R, et al. Stroke vol. 41,2 (2010): e102-9. doi: 10.1161/STROKEAHA.109.564161.
  6. Brott TG, et al. N Engl J Med. 2010 Jul;363(1):11-23. doi: 10.1056/NEJMoa0912321. Epub 2010 May 26.
  7. Kwolek CJ, et al. J Vasc Surg. 2015 Nov;62(5):1227-34. doi: 10.1016/j.jvs.2015.04.460.
  8. U.S. Food and Drug Administration. Summary of safety and effectiveness data (SSED): Roadsaver/CASPER Carotid Stent System (PMA P210030). Published November 20, 2024
  9. Gray WA, et al. J Am Coll Cardiol Intv. 2025 Feb;18(3):367-76. doi: 10.1016/j.jcin.2024.10.031.
  10. Safian RD, et al. J Am Coll Cardiol. 2006 Jun;47(12):2384-89. doi: 10.1016/j.jacc.2005.12.076.
  11. Langhoff R, et al. Cardiovasc Intervent Radiol. 2025 Mar;Vol 48 427–37. doi:10.1007/s00270-025-04003-z.
  12. Wissgott C, et al. J Endovasc Ther 2017;24(1):130-137
  13. Musialek P, Hopkins LN, Sidiiqui AH. Postepy Kardiol Interwencyjnej
Contact Us
Contact Us
Stay Connected